胃肠病学和肝病学:2020年九大科学进展
(滑动下文查看)
1.O'Donnell, M.P., et al., A neurotransmitter produced by gut bacteria modulates host sensory behaviour. Nature, 2020. 583(7816): p. 415-420.
2.Tan, H.E., et al., The gut-brain axis mediates sugar preference. Nature, 2020. 580(7804): p. 511-516.
3.Vaccaro, A., et al., Sleep Loss Can Cause Death through Accumulation of Reactive Oxygen Species in the Gut. Cell, 2020. 181(6): p. 1307-1328.e15.
4.Turpin, W., et al., Increased Intestinal Permeability Is Associated With Later Development of Crohn's Disease. Gastroenterology, 2020. 159(6): p. 2092-2100.e5.
5.Torres, J., et al., Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology, 2020. 159(1): p. 96-104.
6.Chikina, A.S., et al., Macrophages Maintain Epithelium Integrity by Limiting Fungal Product Absorption. Cell, 2020. 183(2): p. 411-428.e16.
7.Tuganbaev, T., et al., Diet Diurnally Regulates Small Intestinal Microbiome-Epithelial-Immune Homeostasis and Enteritis. Cell, 2020. 182(6): p. 1441-1459.e21.
8.Croall, I.D., et al., Cognitive Deficit and White Matter Changes in Persons With Celiac Disease: A Population-Based Study. Gastroenterology, 2020. 158(8): p. 2112-2122.
9.Lebwohl, B., et al., Association Between Celiac Disease and Mortality Risk in a Swedish Population. Jama, 2020. 323(13): p. 1277-1285.
10.Kårhus, L.L., et al., Long-term Consequences of Undiagnosed Celiac Seropositivity. Am J Gastroenterol, 2020. 115(10): p. 1681-1688.
11.Pleguezuelos-Manzano, C., et al., Mutational signature in colorectal cancer caused by genotoxic pks(+) E. coli. Nature, 2020. 580(7802): p. 269-273.
12.Zagato, E., et al., Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. Nat Microbiol, 2020. 5(3): p. 511-524.
13.Fei, N., et al., Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease. mBio, 2020. 11(1).
14.Nanki, K., et al., Somatic inflammatory gene mutations in human ulcerative colitis epithelium. Nature, 2020. 577(7789): p. 254-259.
15.Kakiuchi, N., et al., Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis. Nature, 2020. 577(7789): p. 260-265.
16.Zhou, J., et al., Infection of bat and human intestinal organoids by SARS-CoV-2. Nat Med, 2020. 26(7): p. 1077-1083.
17.Meran, L., et al., Engineering transplantable jejunal mucosal grafts using patient-derived organoids from children with intestinal failure. Nat Med, 2020. 26(10): p. 1593-1601.
18.Nikolaev, M., et al., Homeostatic mini-intestines through scaffold-guided organoid morphogenesis. Nature, 2020. 585(7826): p. 574-578.
19.Choo, Q.L., et al., Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 1989. 244(4902): p. 359-62.
20.Dore, G.J. and J.J. Feld, Hepatitis C virus therapeutic development: in pursuit of 'perfectovir'. Clin Infect Dis, 2015. 60(12): p. 1829-36.
21.Waked, I., et al., Screening and Treatment Program to Eliminate Hepatitis C in Egypt. N Engl J Med, 2020. 382(12): p. 1166-1174.
22.Radley, A., et al., Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. Lancet Gastroenterol Hepatol, 2020. 5(9): p. 809-818.
23.Durand, C.M., et al., The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study. Ann Intern Med, 2018. 168(10): p. 702-711.
24.Woolley, A.E., et al., Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. N Engl J Med, 2019. 380(17): p. 1606-1617.
25.Bethea, E.D., et al., Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. Lancet Gastroenterol Hepatol, 2019. 4(10): p. 771-780.
26.Belperio, P.S., et al., Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients. J Viral Hepat, 2019. 26(8): p. 980-990.
27.Sarrazin, C., et al., No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. J Hepatol, 2018. 69(6): p. 1221-1230.
28.Chung, K.M., et al., Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cell, 2020. 181(4): p. 832-847.e18.
29.Zhang, Z., et al., The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer, 2019. 19(1): p. 511.
30.Kim, S.U., et al., A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. J Hepatol, 2019. 71(3): p. 456-464.
31.Finn, R.S., et al., Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med, 2020. 382(20): p. 1894-1905.
32.Finn, R.S., et al., Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol, 2020. 38(26): p. 2960-2970.
33.Yau, T., et al., Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol, 2020. 6(11).
34.Dominguez, C.X., et al., Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15(+) Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer Discov, 2020. 10(2): p. 232-253.
35.Sakamoto, H., et al., The Evolutionary Origins of Recurrent Pancreatic Cancer. Cancer Discov, 2020. 10(6): p. 792-805.
36.Segovia-Miranda, F., et al., Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression. Nat Med, 2019. 25(12): p. 1885-1893.
37.Newsome, P.N., et al., FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol, 2020. 5(4): p. 362-373.
38.Younossi, Z.M., et al., Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 2019. 394(10215): p. 2184-2196.
作者|拍了花宝贝、617